Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Brian S. Seal"'
Autor:
Tasneem Lokhandwala, Abdalla Aly, Eileen Farrelly, Joanne P Willey, Lois E Lamerato, Marcus Healey, Anna D Coutinho, Brian S Seal
Publikováno v:
Hepatic Oncology, Vol 9, Iss 4 (2022)
Aim: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. Materials & methods: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2
Externí odkaz:
https://doaj.org/article/a2b0419ef36041ee82d2d7a227927037
Autor:
Candice Yong, Ranee Mehra, Kelly Clapp, Brian S. Seal, Ion Cotarla, M. Janelle Cambron-Mellott, Emily Mulvihill, Oliver Will, Martine C Maculaitis
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-106
Autor:
Pradeep J. Poonnen, Kyung Min Lee, Anna Hung, Trudy Pendergraft, Julie Lynch, Bradley J. Hintze, Shelby D. Reed, Yanhong Li, Candice Yong, Michael J. Kelley, Olga V. Efimova, Brian S. Seal
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-086
Autor:
David Merola, Lance Brannman, Candice Yong, Brian S. Seal, Meghan J. Mooradian, Kenneth M. Shermock
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-101
Autor:
Arif Hussain, James F. Gardner, Chandana A. Reddy, Jinani Jayasekera, Eberechukwu Onukwugha, Jay P. Ciezki, Sana Malik, Adriana Valderrama, Brian S. Seal, C. Daniel Mullins, Young Kwok
Publikováno v:
JCO Clinical Cancer Informatics. :1-12
Purpose There is limited information on the use of data visualization tools for health services research applications. We provide a proof-of-concept application that focuses on claims-based measures of palliative radiation therapy. We investigate whe
Autor:
Yiqiong Xie, Brian S. Seal, Candice Yong, David M. Waterhouse, Nicholas J. Robert, Kathleen M. Aguilar, Ion Cotarla, Juliet Ndukum
Publikováno v:
Journal of Clinical Oncology. 39:295-295
295 Background: While the introduction of durvalumab consolidation therapy shifted the treatment paradigm for unresectable stage III NSCLC, few studies have examined real-world use of durvalumab in this patient population. Methods: This was a retrosp
Autor:
Nicholas J. Robert, Petros Grivas, Kathleen M. Aguilar, Kalatu Davies, Mark D. Fleming, Brian S. Seal
Publikováno v:
Journal of Clinical Oncology. 39:293-293
293 Background: ICI approval provided new treatment options for patients (pts) with u/mUC. We aimed to assess the adoption of ICI and describe 1L treatment patterns in the US community oncology setting. We hypothesized that most pts would receive ICI
Autor:
Brian S. Seal, Shasank Chennupati, Veena Shankaran, Hayley Sanchez, Qin Sun, Abdalla Aly, Healey Marcus
Publikováno v:
Journal of Clinical Oncology. 39:e16149-e16149
e16149 Background: Though the treatment landscape for HCC has changed significantly in the last several years with the refinement of liver-directed therapy techniques and the introduction of multiple new drugs, few studies have investigated the impac
Autor:
Eberechukwu Onukwugha, C. Daniel Mullins, Nader Hanna, Brian S. Seal, Kaloyan A. Bikov, Anna Hung
Publikováno v:
The Oncologist. 21:676-683
We explored biologics receipt in metastatic colon cancer.We used Surveillance, Epidemiology, and End Results-Medicare data of 4,545 elderly patients diagnosed with incident metastatic colon cancer from 2003 to 2009, treated with chemotherapy and/or b
Autor:
Charles B. Simone, Ramesh Rengan, Jingxuan Zhao, Zhiyuan Zheng, Stephen G. Chun, Brian S. Seal, Xuesong Han, Doris Makari, Helmneh M. Sineshaw, Candice Yong
Publikováno v:
Journal of Clinical Oncology. 38:2069-2069
2069 Background: Recent data suggests that a significant number of good performance, unresectable stage III non-small cell lung cancer (NSCLC) patients do not receive standard-of-care treatment, i.e. concurrent chemoradiotherapy (cCRT) followed by du